Blueprint Medicines — 2017 ASCO Annual Meeting
41 slides from Blueprint Medicines's conference presentation, Jun 6, 2017
Slide 1: 2017 ASCO Annual Meeting: Advances in GIST
2017 ASCO Annual Meeting Monday, June 5, 2017 Advances in GIST
Slide 2: Forward-looking statements
Forward-looking statements 2 This presentation contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. The words “may,” “will,” “could,” “would,” “should,” “expect,” “plan,” “anticipate,” “intend,” “believe,” “estimate,” “predict,” “project
Slide 3: Agenda
Agenda Welcome Jeff Albers, Chief Executive Officer, Blueprint Medicines Overview of BLU-285 in GIST Andy Boral, MD, Chief Medical Officer, Blueprint Medicines Phase 1 clinical trial results Michael Heinrich, MD, Professor, Oregon Health and Science University Proposed registration path Andy Boral,
Slide 4: Targeted kinase medicines for genomically defined diseases
Medicinal chemistry Proprietary compound library Genomic targeting A blueprint for a healthier tomorrow 4 Targeted kinase medicines for genomically defined diseases Discovery platform for exquisitely selective kinase inhibitors, matched to specific molecular drivers of disease, with rapid path to cl
Slide 5: A new way of looking at kinase medicines
A new way of looking at kinase medicines Kinome illustration reproduced courtesy of CSTI (cellsignal.com). The foregoing website is maintained by CSTI, and Blueprint Medicines is not responsible for its content; IO, immuno-oncology 5 BLU-554 Nexavar Sutent BLU-285 We aim to design and develop highly
Slide 6: Three major areas of focus
Three major areas of focus 6 Genomically defined cancers Rare diseases Cancer immunotherapy Oncogenic kinases resulting from tumor genetic alterations BLU-285 gastrointestinal stromal tumors BLU-554 hepatocellular carcinoma BLU-667 RET-altered cancers Abnormally activated kinases due to rare genetic
Slide 7: Robust pipeline of diverse clinical stage assets
Drug candidate Discovery Preclinical Clinical Commercial rights BLU-285 Inhibitor of KIT, including exon 17 mutations, and PDGFRα, including the D842V mutation BLU-554 Inhibitor of FGFR4 BLU-667 Inhibitor of RET fusions, mutations and resistant mutants PRKACA Inhibitor of PRKACA fusions Cancer immun
Slide 8: Gastrointestinal stromal tumors (GIST)
Gastrointestinal stromal tumors (GIST) Colon and rectum 5% Small intestine 30% Stomach 60% Duodenum 5% Primary tumor sites 9 Typically presents as stomach or intestinal mass Metastases in liver, peritoneum and other distant sites Mutant receptor tyrosine kinases are key disease drivers PDGFRα ~5-10%
Slide 9: PDGFRα and KIT activation loop mutations stabilize active conformation
PDGFRα and KIT activation loop mutations stabilize the kinase active conformation, blocking binding of type 2 inhibitors Imatinib is a type 2 multikinase inhibitor that cannot bind the kinase active conformation due to a steric clash BLU-285 is a type 1 selective PDGFRα/KIT inhibitor that binds to t
Slide 10: Currently available therapies do not effectively address activation loop mutations
Currently available therapies do not effectively address activation loop mutations *Estimated incidence for GIST patients in major markets (US, EU5 and Japan). **Estimated frequency of Exon 17 activation loop mutations. 11 PDGFRα D842V ALL GIST 1L imatinib PFS ~3 months ORR ~0% ~500 patients* 1L ima
Slide 11: Promising preclinical data supported initiation of Phase 1 trial of BLU-285
Promising preclinical data supported initiation of a Phase 1 clinical trial of BLU-285 in advanced GIST Most potent biochemical activity against activation loop mutants Biochemical activity across a broad PDGFRα and KIT mutational spectrum 12 Biochemical IC50 (nM) Data previously presented in April
Slide 12: Updated Phase 1 clinical trial results
Updated Phase 1 clinical trial results Michael C. Heinrich, M.D. Oregon Health & Sciences University (OHSU)
Slide 13: Clinical activity of BLU-285 in advanced GIST
GIST: imatinib and beyond Clinical activity of BLU-285 in advanced gastrointestinal stromal tumor (GIST) Michael Heinrich1, Robin Jones2, Margaret von Mehren3, Patrick Schoffski4, Sebastian Bauer5, Olivier Mir6, Philippe Cassier7, Ferry Eskens8, Hongliang Shi9, Terri Alvarez-Diez9, Oleg Schmidt-Kitt
Slide 14: Disclosures
Disclosures BLU-285 is an investigational agent currently in development by Blueprint Medicines Corporation (Blueprint Medicines) Dr. Michael Heinrich is an investigator for Blueprint Medicines’ ongoing Phase 1 studies in unresectable gastrointestinal stromal tumor Dr. Michael Heinrich has the follo
Slide 15: Imatinib revolutionized GIST treatment
Imatinib revolutionized Gastrointestinal Stromal Tumor (GIST) treatment Imatinib binds the inactive kinase conformation and inhibits many primary mutants Imatinib is a highly effective first-line GIST therapy A-loop imatinib A-loop imatinib Inactive conformation Active conformation KIT KIT mutations
Slide 16: Beyond imatinib, there are no highly effective therapies
Beyond imatinib, there are no highly effective therapies1–6 Primary resistance Secondary resistance 3L regorafenib 1L imatinib 2L sunitinib ORR ~60% PFS 19 mo ORR ~7% PFS 6 mo 4L no approved therapy ORR ~5% PFS 4.8 mo ORR ~0% PFS ≤1.8 mo* 17 Prevalence7,8 Resistance mutation Primary Secondary PDGFRα
Slide 17: BLU-285: highly potent and selective targeting of KIT/PDGFR GIST mutants
BLU-285: highly potent and selective targeting of KIT/PDGFR GIST mutants 18 High kinome selectivity* Binds active conformation BLU-285 *Image reproduced courtesy of CSTI (www.cellsignal.com)
Slide 18: BLU-285: highly active against imatinib-resistant GIST xenografts
KIT exon 11/17 mutant KIT exon 11/13 mutant BLU-285: highly active against imatinib-resistant GIST patient derived xenografts Tumor regression at 10 and 30 mg/kg QD Tumor regression at 30 mg/kg QD 19
Slide 19: BLU-285 Phase 1 study design
BLU-285 Phase 1 study Advanced GIST MTD Part 2 Dose expansion enrolling Unresectable GIST after imatinib and ≥1 other TKI (n=50) PDGFR D842V-mutant GIST (n=50) Part 1 Dose escalation completed Key objectives Part 1: MTD, safety, pharmacokinetics, ctDNA analyses, anti-tumor activity Part 2: response
Slide 20: Demography and baseline patient characteristics
Demography and baseline patient characteristics Parameter All patients, N=72 Age (years), median (range) 61 (25–85) n (%) GIST subtype KIT mutant PDGFR mutant 40 (56) 32 (44) Metastatic disease 69 (96) Largest target lesion size (cm) ≤5 >5–≤10 >10 18 (25) 25 (35) 29 (40) No. prior kinase inhibitors
Slide 21: BLU-285 pharmacokinetics support QD dosing
BLU-285 pharmacokinetics support QD dosing and broad mutational coverage Relatively rapid absorption Tmax ~2–8 hours and long half-life >24 hours Exposure at the 300 and 400 (MTD) mg provides broad coverage of primary and secondary KIT/PDGFR mutations based on patient derived xenografts (PDX) 22 *i
Slide 22: Radiographic response in PDGFR D842V-mutant GIST
Radiographic response per RECIST 1.1 in PDGFR D842V-mutant GIST Ongoing at cycle 5 Prior imatinib and sunitinib Confirmed PR, -63% target sum Ongoing at cycle 3 Prior imatinib PR (pending confirmation), -85% target sum Target lesion resolution Baseline After 4 months BLU-285 300 mg (dose escalation
Slide 23: Tumor regression across all dose levels in PDGFR D842-mutant GIST
Tumor regression across all dose levels in PDGFR D842-mutant GIST (central radiology review) 24
Slide 24: High response rate and prolonged PFS in PDGFR D842-mutant GIST
High response rate and prolonged PFS in PDGFR D842-mutant GIST Best response (N=25) Choi Criteria n (%) RECIST 1.1 n (%) PR 25 (100%) 15* (60%) SD 0 10 (40%) DCR (PR + SD) 25 (100%) 25 (100%) PD 0 0 Central radiographic review Approved agents are ineffective1,2 ORR ~0% * 12 confirmed, 3 pending con
Slide 25: Radiographic response in heavily pre-treated KIT-mutant GIST
Radiographic response in heavily pre-treated KIT-mutant GIST Ongoing at cycle 12 6 prior TKIs; exon 11, 13, and 18 mutations CHOI PR (density -53%); RECIST SD (-21%) Screening Cycle 3 Cycle 5 Cycle 7 Ongoing at cycle 4 5 prior TKIs; 1 exon 11 mutation; ctDNA pending CHOI PR (density -76%); RECIST P
Slide 26: Dose-dependent tumor reduction across multiple KIT genotypes
Dose-dependent tumor reduction across multiple KIT genotypes (central radiographic review) 27 *ctDNA results pending **per archival tumor and ctDNA
Slide 27: Adverse events associated with BLU-285
Adverse events (AE) associated with BLU-285 18 (25%) patients had Grade (G) ≥3 treatment-related (Fatigue [8%], hypophosphatemia [6%], anemia [4%], nausea, vomiting, hyperbilirubinemia [3% each]) DLT in 2 patients at 600 mg: 1 G2 hyperbilirubinemia; 1 G2 rash, hypertension, memory impairment BLU-285
Slide 28: Conclusions
Conclusions BLU-285 is well tolerated on a QD schedule at doses up to the MTD of 400 mg Exposure at 300–400 mg QD provides broad coverage of primary and secondary KIT / PDGFR mutants BLU-285 has strong clinical activity in PDGFR D842-mutant GIST with an ORR of 60% per central review and median PFS
Slide 29: Acknowledgments
Acknowledgments We thank the participating patients, their families, all study co-investigators, and research coordinators at the following institutions: Oregon Health & Sciences University Royal Marsden Hospital/Institute for Cancer Research Leuven Cancer Institute University of Essen Fox Chase Can
Slide 30: References
References Cassier et al. Clin Cancer Res. 2012;18(16):4458–64 Yoo et al. Cancer Res Treat. 2016;48(2):546–52 Kang et al. Lancet Oncol. 2013;14(12):1175–82 National Comprehensive Cancer Network. Gastrointestinal Stromal Tumors. 2016 Demetri et al. Lancet. 2006;368:1329 Demetri et al. Lancet. 2013;38
Slide 31: Proposed registration path
Proposed registration path Andy Boral, M.D. Chief Medical Officer
Slide 32: BLU-285 clinical development program in advanced GIST
BLU-285 clinical development program in advanced GIST 34 Dose escalation (N=36) PDGFRα D842V expansion cohort (N=50) ≥3L KIT expansion cohort (N=50) Ongoing Phase 1 clinical trial 3L GIST Breakthrough Therapy Designation granted for treatment of patients with unresectable or metastatic GIST harborin
Slide 33: Strong clinical activity in PDGFRα D842V-driven GIST supports expedited approach
Strong clinical activity in PDGFRα D842V-driven GIST supports expedited approach to clinical development Best Response Choi Criteria (N = 25) mRECIST 1.1 (N = 25) PR 25 (100%) 15* (60%) SD 0 10 (40%) DCR (PR + SD) 25 (100%) 25 (100%) PD 0 0 Central Radiographic Review Approved agents are ineffective
Slide 34: Preliminary FDA feedback supports potentially expedited approval path
Preliminary FDA feedback supports potentially expedited approval path for BLU-285 in PDGFRα D842V-driven GIST Breakthrough Therapy Designation granted for treatment of patients with unresectable or metastatic GIST harboring the PDGFRα D842V mutation FDA is open to considering additional data from on
Slide 35: Prolonged PFS demonstrated in 5L KIT-driven GIST
Prolonged progression free survival demonstrated in 5L KIT-driven GIST ↑PFS with BLU-285 ≥ 300 mg Prior kinase inhibitor treatment Median of 4 therapies 90% had ≥3 therapies 85% had regorafenib Regorafenib PFS in 3L ~4.8 months 37 Stable disease is clinically important to patients and physicians
Slide 36: Clinical activity supports advancing BLU-285 into earlier lines of treatment
Encouraging clinical activity supports advancing clinical development of BLU-285 into earlier lines of treatment Potential Phase 3 trial design: Population: 3L GIST Comparator: regorafenib, with option to cross-over to BLU-285 Primary endpoint: PFS Trial sites: global Investigators and expert adviso
Slide 37: Progress in advanced GIST represents a foundation for a broader vision
Progress in advanced GIST represents a foundation for a broader vision 39 BLU-285 PDGFRα-driven advanced GIST 3L advanced GIST 2L advanced GIST Advanced systemic mastocytosis Indolent systemic mastocytosis KIT- and PDGFRα-driven diseases
Slide 38: Question & Answer Session
Question & Answer Session {Sbwueprint
Slide 39: Closing Remarks
Closing Remarks Jeff Albers Chief Executive Officer 41
Slide 40: Robust pipeline of diverse clinical stage assets
Drug candidate Discovery Preclinical Clinical Commercial rights BLU-285 Inhibitor of KIT, including exon 17 mutations, and PDGFRα, including the D842V mutation BLU-554 Inhibitor of FGFR4 BLU-667 Inhibitor of RET fusions, mutations and resistant mutants PRKACA Inhibitor of PRKACA fusions Cancer immun
Slide 41: Additional clinical data updates for BLU-285 and BLU-554 expected in 2H 2017
With maturing datasets, additional clinical data updates for BLU-285 and BLU-554 are expected in 2H 2017 Opportunity Previously presented Phase 1 data** BLU-285 in systemic mastocytosis BLU-554 in hepatocellular carcinoma Poor prognosis and limited effective treatments KIT D816V mutation is a key dr